B. Riley initiated coverage on shares of Arbutus Biopharma (NASDAQ:ABUS) in a research note published on Friday morning, MarketBeat reports. The brokerage issued a buy rating and a $10.00 price objective on the biopharmaceutical company’s stock.
ABUS has been the topic of a number of other research reports. JMP Securities reaffirmed an outperform rating and set a $13.00 price objective (up previously from $12.00) on shares of Arbutus Biopharma in a research note on Wednesday, October 4th. Chardan Capital reaffirmed a buy rating on shares of Arbutus Biopharma in a research note on Wednesday, September 13th. Zacks Investment Research raised shares of Arbutus Biopharma from a sell rating to a hold rating in a research note on Tuesday, November 7th. Wedbush reaffirmed an outperform rating and set a $9.00 price objective on shares of Arbutus Biopharma in a research note on Wednesday, September 20th. Finally, BidaskClub raised shares of Arbutus Biopharma from a sell rating to a hold rating in a research note on Thursday, January 4th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of $12.50.
Shares of Arbutus Biopharma (ABUS) opened at $5.10 on Friday. The company has a market cap of $280.77, a P/E ratio of -1.02 and a beta of 1.07. Arbutus Biopharma has a one year low of $2.35 and a one year high of $8.25. The company has a debt-to-equity ratio of 0.08, a quick ratio of 11.03 and a current ratio of 11.03.
ILLEGAL ACTIVITY NOTICE: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.com-unik.info/2018/01/09/arbutus-biopharma-abus-coverage-initiated-at-b-riley.html.
About Arbutus Biopharma
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.